£8.0M
Parkwalk Advisors spearheaded the round to help the medical technology company prepare for human trials.
Oxford Endovascular
Oxford Endovascular develops origami-inspired medical devices for brain aneurysm treatment.
£15.3MTotal raised
Oxford Endovascular is a medical technology company developing origami-inspired medical devices to treat brain aneurysms.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from Oxford Endovascular's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
Mike Karim
CEO
Mike brings healthtech and commercial experience from roles including chief executive officer at Oxford Endovascular and chief commercial officer at Medistim ASA. He also serves as a venture partner at Synapto Ventures and a non-executive board member at OBN.
LinkedInInvestors
- £8.0MVVulpesFollow-onUoUniversity of OxfordFollow-on
- £7.3M
Funding history
£7.3M
The financing round was led by Vulpes Investment Management with backing from existing investors to fund first in-human data acquisition.